

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

22-043

APPROVAL LETTER



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 22-043

Janssen, L.P.

C/O Johnson & Johnson Pharmaceutical Research and Development, L.L.C.

Attention: Heddie Martynowicz, M.S., Director Regulatory Affairs

1125 Trenton-Harbourton Road

P.O. Box 200

Titusville, NJ 08560

Dear Ms. Martynowicz:

Please refer to your new drug application (NDA) dated and received June 27, 2006, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Invega (paliperidone) 3, 6, 9, 12 mg Extended-Release Tablets.

We acknowledge receipt of your submissions dated:

October 27, 2006

December 21, 2006

January 26, 2007

March 8, 2007

This new drug application provides for the use of Invega (paliperidone) Extended-Release Tablets for the maintenance treatment of schizophrenia.

We completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text (email of April 26, 2007).

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert). Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. For administrative purposes, designate this submission "**FPL for approved NDA 22-043.**" Approval of this submission by FDA is not required before the labeling is used.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We are waiving the pediatric study requirement for this application.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this division and two copies of both the promotional materials and the package insert directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

All 15-day alert reports, periodic (including quarterly) adverse drug experience reports, field alerts, annual reports, supplements, and other submissions should be addressed to the original NDA 21-999 for this drug product, not to this NDA. In the future, do not make submissions to this NDA except for the final printed labeling requested above.

If you have any questions, call Keith Kiedrow, Pharm.D., Regulatory Project Manager, at (301) 796-1924.

Sincerely,

{See appended electronic signature page}

Thomas Laughren, M.D.
Director
Division of Psychiatry Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosure